The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

The price hike is causing private patients to switch to the competitor drug Ozempic, with sales of the latter reportedly surging by 500 to 600 per cent. Eli Lilly said the price adjustment is to align ...